Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000530072 | SCV000627845 | uncertain significance | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2017-05-27 | criteria provided, single submitter | clinical testing | In summary, this variant has uncertain impact on FBN1 function. The available evidence is currently insufficient to determine its role in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with a FBN1-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with glutamic acid at codon 621 of the FBN1 protein (p.Gly621Glu). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and glutamic acid. |
Institute for Clinical Genetics, |
RCV003321645 | SCV004026413 | uncertain significance | not provided | 2023-07-21 | criteria provided, single submitter | clinical testing | PP3, PM2_SUP, PP2 |